Highlights Sanofi

Stocks

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 19:55:00 10/07/2026 +04			5-day change	1st Jan Change
76.23 ^EUR	-0.33%		+0.55%	-7.85%

07-10	Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector	CI
07-10	Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma	MT

Highlights

07-10	Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector	CI
07-10	Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma	MT
07-08	Sanofi to Address Competition Concerns Over Communication Campaign, European Commission Says	MT
07-08	EU Seeks Views on Sanofi's Concessions to End Competition Probe -- Update	DJ
07-08	EU Commission Seeks Comments on Sanofi's Commitments in Anticompetitive Probe	MT
07-08	EU Seeks Views on Sanofi's Concessions to End Competition Probe	DJ
07-08	AlphaValue/Baader Europe Cuts Sanofi Price Target After Scrapped Late-Stage Rare Neurological Disease Trial	MT
07-02	Sanofi rebounds, Oddo BHF reiterates its bullish view
07-01	FDA clears Orca's blood cancer therapy to reduce stem cell transplant complications	RE
06-30	Sanofi Nexviazyme Meets All Primary and Secondary Endpoints in Infantile-Onset Pompe Disease Phase 3 Study	CI
06-29	Sanofi Faces European Commission Investigation into Anticompetitive Conduct Regarding Flu Vaccine Promotion	CI
06-26	Sanofi Unit Wins European Medicines Agency Panel's Positive Opinion for Extension of Meningococcal Disease Vaccine's Indication	MT
06-26	Sanofi Faces EU Antitrust Probe Over Flu Vaccine Communication Campaign	MT
06-26	Sanofi Probed by EU Over Flu Vaccine Marketing	DJ
06-26	European Commission investigation into Sanofi
06-26	EU Commission Opens Probe into Sanofi Over Possible Anticompetitive Flu Vaccine Promotion	MT
06-26	EU Commission Opens Probe into Sanofi Over Possible Anticompetitive Flu Vaccine Promotion	MT
06-26	EU Commission opens antitrust probe into Sanofi's flu vaccine campaign	RE
06-23	Department Of Health ? Abu Dhabi And Sanofi Partner To Advance Vaccine Innovation	CI
06-23	Sanofi Receives Marketing and Manufacturing Authorization to Wayrilz (Rilzabrutinib) from the Ministry of Health, Labour and Welfare in Japan	CI
06-23	Sanofi Receives European Commission Approval For Cenrifki (Tolebrutinib) As The First Disability-Targeting Medicine For Secondary Progressive Multiple Sclerosis Without Relapses	CI
06-23	Sanofi and Abu Dhabi's Health Department Sign MoU to Explore Vaccine Innovation Centre	MT
06-23	Sanofi Wins EU Nod for Secondary Progressive Multiple Sclerosis Treatment	MT
06-23	Sanofi Wins Japanese Approval for Thrombocytopenia Treatment Wayrilz	MT
06-23	Sanofi, Abu Dhabi Health Department Partner on Vaccine Innovation Center Initiative	MT